Form DEF 14A MaxCyte For: 29 April
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
MaxCyte Inc (MXCT)
The MaxCyte share price today is 0.861, view NASDAQ MXCT stock exchange data. Track the latest MaxCyte share price with real-time updates on MXCT stock performance including market cap, day range, 52-week range and dividend yield. Access MXCT charts, earnings dates and analyst estimates to support your investment decisions.
0.861
+0.043(+5.25%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.790
0.871
52 wk Range
0.643
2.875
Earnings results expected in 13 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.7900.871
52 wk Range
0.6432.875
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MXCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
4.108
Upside
+377.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- MaxCyte NAQ receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13G MAXCYTE For: 10 April
- Investing.com
- MaxCyte NAQ receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K MaxCyte Inc For: 27 March
- Investing.com
- Form DEF 14A MaxCyte For: 29 April
- Investing.com
- Form 13G MAXCYTE For: 10 April
- Investing.com
- Form 8K MaxCyte Inc For: 27 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.108
(+377.06% Upside)
MaxCyte Inc Earnings Call Summary for Q4/2025
- MaxCyte missed Q4 2025 forecasts with EPS of -$0.09 vs. -$0.08 expected; revenue fell 22% short at $7.3M vs. $9.36M projected.
- Annual revenue declined to $33M from $38.6M in 2024; stock dropped 76% over past year, trading near 52-week low at $0.747.
- Company launched ExPERT DTx platform, expecting meaningful revenue contributions in second half of 2026 and beyond.
- Maintains strong balance sheet with $136M+ cash expected by end of 2026 and no debt despite ongoing financial pressures.
- Parmeet Ahuja joins as CFO; faces challenges from declining core revenue, customer consolidation, and biotech funding uncertainties.
Last Updated: 25-03-2026, 02:54 am
Read Full TranscriptEarnings
Latest Release
24-03-2026
EPS / Forecast
-0.09 / -0.08
Revenue / Forecast
7.3M / 9.36M
Compare MXCT to Peers and Sector
Metrics to compare | MXCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMXCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −3.4x | −0.5x | |
PEG Ratio | 0.28 | 0.00 | 0.00 | |
Price/Book | 0.5x | 1.0x | 2.6x | |
Price / LTM Sales | 2.7x | 3.2x | 3.2x | |
Upside (Analyst Target) | - | 69.3% | 50.8% | |
Fair Value Upside | Unlock | 24.9% | 7.7% | Unlock |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the MaxCyte (MXCT) Share Price Today?
The MaxCyte share price today is 0.861.
What is the current MaxCyte (MXCT) share price and day range?
As of 30-04-2026, the MaxCyte share price is 0.861, with a previous close of 0.818. The share price has ranged from 0.790 to 0.871 today, while the 52-week range spans from 0.643 to 2.875.
What Is the MaxCyte Market Cap?
As of today, MaxCyte market cap is 90.940M.
What Is the MaxCyte (MXCT) Share Price Target?
The average 12-month share price target for MaxCyte is 4.108, with a high estimate of 5 and a low estimate of 2.43. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +377.06% Upside potential.
What Is MaxCyte's Earnings Per Share (TTM)?
The MaxCyte EPS (TTM) is -0.419.
When Is the Next MaxCyte Earnings Date?
MaxCyte will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is MXCT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does MaxCyte Trade On?
MaxCyte is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for MaxCyte?
The stock symbol for MaxCyte is "MXCT."
How Many Times Has MaxCyte Stock Split?
MaxCyte has split 0 times.
How Many Employees Does MaxCyte Have?
MaxCyte has 91 employees.
What Is the MXCT Premarket Price?
MXCT's last pre-market stock price is 0.824. The pre-market share volume is 5,580.000, and the stock has changed by 0.006, or 0.730%.
What Is the MXCT After Hours Price?
MXCT's last after hours stock price is 0.800, the stock has changed by -0.018, or -2.150%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.